Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$42.67 USD
+0.03 (0.07%)
Updated Jul 22, 2024 04:00 PM ET
Pre-Market: $42.72 +0.05 (0.12%) 9:04 AM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMY 42.67 +0.03(0.07%)
Will BMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
Other News for BMY
Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline
Bristol Myers price target lowered by $8 at Deutsche Bank, here's why
Alumis initiated with bullish view at Leerink, here's why
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
Johnson & Johnson: Seriously Undervalued At Peak Pessimism